Diagnostic follow-up of well-differentiated thyroid carcinoma: Historical perspective and current status

Journal of Endocrinological Investigation

Volumn 22, Issue 11 SUPPL. 1, 1999, Pages 3-7

  Schlumberger, M J ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Indine 131 whole body scanning; Prognostic factors; Recombinant human thyroid stimulating hormone; Serum thyroglobulin testing; Well differentiated thyroid cancer

Indexed keywords

DIAGNOSTIC AGENT; THYROGLOBULIN; THYROTROPIN; THYROXINE;

ADENOCARCINOMA; BLOOD; HUMAN; METASTASIS; PAPILLARY CARCINOMA; PROGNOSIS; REVIEW; RISK FACTOR; THYROID TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; THYROXINE;

EID: 0033255336     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics, 1997. CA Cancer J. Clin. 1997, 47: 5.
2. Schlumberger M., Pacini F. Thyroid Tumors. Editions Nucléon, Paris, 1999, p. 1.
3. Schlumberger M.J. Papillary and follicular thyroid carcinoma [Medical progress]. N. Engl. J. Med. 1998, 338: 297.
4. Tubiana M., Schlumberger M., Rougier P., Laplanche A., Benhamou E., Gardet P., Caillou B., Travagli J.P., Parmentier C. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985, 55: 794.
5. Byar D.P., Green S.B., Dor P., Williams E.D., Colon J., van Gilse H.A., Mayer M., Sylvester R.J., van Glabbeke M. A prognostic index for thyroid carcinoma: a study of the EORTC Thyroid Cancer Cooperative Group. Eur. J. Cancer 1979, 15: 1033.
6. Hay I.D., Bergstralh E.J., Goellner J.R., Ebersold J.R., Grant C.S. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993, 114: 1050.
7. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 1994, 97: 418.
8. Cady B., Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988, 104: 947.
9. DeGroot L.J., Kaplan E.L., McCormick M., Straus F.H. Natural history, treatment and course of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1990, 71: 414.
10. Schlumberger M., De Vathaire F., Travagli J.P., Vassal G., Lemerle J., Parmentier C., Tubiana M. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J. Clin. Endocrinol. Metab. 1987, 65: 1088.
11. Vassilopolou-Sellin R., Klein M.J., Smith T.H. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 1993, 71: 1348.
12. Sakamoto A., Kasai N., Sugano H. Poorly differentiated carcinoma of the thyroid: a clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 1983, 52: 1849.
13. Van Herle A.J., Uller R.P., Matthews N.I., Brown J. Radioimmunoassay for measurement of thyroglobulin in human serum. J. Clin. Invest. 1973, 52: 1320.
14. Spencer C.A., Takeuchi M., Kazarosyan M., Wang C.C., Gutler R.B., Singer P.A., Fatemi S., LoPresti J.S., Nicoloff J.T. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 1998, 83: 1121.
15. Schlumberger M.J., Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 1998, 138: 249.
16. Schlumberger M., Arcangioli O., Piekarski J.D., Tubiana M., Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J. Nucl. Med. 1988, 29: 1790.
17. Pacini F., Lippi F., Formica N., Elisei R., Anelli S., Ceccarelli C., Pinchera A. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J. Nucl. Med. 1987, 28: 1888.
18. Pineda J.D., Lee T., Ain K., Reynolds J.C., Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J. Clin. Endocrinol. Metab. 1995, 80: 1488.
19. Uller R.P., Van Herle A.J., Chopra I.J. Comparison of alterations in circulating thyroglobulin, triiodothyronine and thyroxine in response to exogenous (bovine) and endogenous (human) thyrotropin. J. Clin. Endocrinol. Metab. 1973, 37: 741.
20. Schlumberger M., Charbord P., Fragu P., Lumbroso J., Parmentier C., Tubiana M. Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyrotropin levels. J. Clin. Endocrinol. Metab. 1980, 51: 513.
21. Dow K.H., Ferrell B.R., Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997, 7: 613.